drugset / Trial / NCT00165854

Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer

NCT00165854

Phase 2 Completed 46 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Part 1: The primary purpose is to determine the recommended dose of E7070 in combination with capecitabine by dose adjustment. Part 2: The primary purpose is to determine the safety and efficacy of the combination in patients with metastatic CRC resistant to 5-fluorouracil and irinotecan.

Timeline

Start
2003-03
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject indisulam Small molecule

Indications